Bayer (BAYN) Receives Buy Rating from Citigroup
Other equities analysts have also recently issued research reports about the stock. Barclays set a €105.00 ($125.00) target price on shares of Bayer and gave the stock a sell rating in a report on Monday, November 6th. Goldman Sachs Group set a €125.00 ($148.81) target price on shares of Bayer and gave the stock a buy rating in a report on Tuesday, November 7th. UBS set a €125.00 ($148.81) target price on shares of Bayer and gave the stock a buy rating in a report on Monday, November 6th. Berenberg Bank set a €124.00 ($147.62) target price on shares of Bayer and gave the stock a neutral rating in a report on Friday, November 3rd. Finally, Jefferies Group set a €137.00 ($163.10) target price on shares of Bayer and gave the stock a buy rating in a report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. Bayer has an average rating of Buy and an average target price of €122.19 ($145.46).
Shares of Bayer (FRA BAYN) traded up €0.55 ($0.65) during trading hours on Thursday, reaching €104.70 ($124.64). The company’s stock had a trading volume of 2,253,861 shares. Bayer has a 52-week low of €90.26 ($107.45) and a 52-week high of €123.82 ($147.40).
TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/bayer-bayn-receives-buy-rating-from-citigroup/1752432.html.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with Analyst Ratings Network's FREE daily email newsletter.